BridGene Biosciences Announces Research Collaboration with Takeda to Discover Small Molecule Drugs for “Undruggable” Targets
BridGene Eligible to Receive More Than $500 Million in Potential Upfront and Milestone Payments Sunnyvale, CA, March 30, 2021 – BridGene Biosciences, Inc., a biotechnology company using cutting-edge technology to discover and develop small molecules for hard-to-drug therapeutic targets, announced today …